

Casey M Theriot

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3303399/casey-m-theriot-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

3,077
citations

23
h-index

52
g-index

52
ext. papers

4,415
ext. citations

8.5
avg, IF

5.84
L-index

#	Paper	IF	Citations
46	Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to <i>Clostridium difficile</i> infection. <i>Nature Communications</i> , 2014 , 5, 3114	17.4	568
45	Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. <i>Science</i> , 2018 , 360,	33.3	503
44	Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for <i>Clostridium difficile</i> Spore Germination and Outgrowth in the Large Intestine. <i>MSphere</i> , 2016 , 1,	5	216
43	The interplay between microbiome dynamics and pathogen dynamics in a murine model of <i>Clostridium difficile</i> infection. <i>Gut Microbes</i> , 2011 , 2, 145-58	8.8	192
42	Interactions Between the Gastrointestinal Microbiome and <i>Clostridium difficile</i> . <i>Annual Review of Microbiology</i> , 2015 , 69, 445-61	17.5	167
41	High-throughput amplicon sequencing of the full-length 16S rRNA gene with single-nucleotide resolution. <i>Nucleic Acids Research</i> , 2019 , 47, e103	20.1	155
40	Hydrolysis of organophosphorus compounds by microbial enzymes. <i>Applied Microbiology and Biotechnology</i> , 2011 , 89, 35-43	5.7	123
39	Cefoperazone-treated mice as an experimental platform to assess differential virulence of <i>Clostridium difficile</i> strains. <i>Gut Microbes</i> , 2011 , 2, 326-34	8.8	113
38	Dynamics and establishment of <i>Clostridium difficile</i> infection in the murine gastrointestinal tract. <i>Infection and Immunity</i> , 2015 , 83, 934-41	3.7	100
37	Diversification of host bile acids by members of the gut microbiota. <i>Gut Microbes</i> , 2020 , 11, 158-171	8.8	95
36	Inhibition of spore germination, growth, and toxin activity of clinically relevant <i>C. difficile</i> strains by gut microbiota derived secondary bile acids. <i>Anaerobe</i> , 2017 , 45, 86-100	2.8	94
35	Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent <i>Clostridium difficile</i> infection. <i>Anaerobe</i> , 2018 , 53, 64-73	2.8	81
34	Fecal Microbiota Transplantation Eliminates <i>Clostridium difficile</i> in a Murine Model of Relapsing Disease. <i>Infection and Immunity</i> , 2015 , 83, 3838-46	3.7	76
33	Bile salt hydrolases: Gatekeepers of bile acid metabolism and host-microbiome crosstalk in the gastrointestinal tract. <i>PLoS Pathogens</i> , 2019 , 15, e1007581	7.6	75
32	Impact of microbial derived secondary bile acids on colonization resistance against <i>Clostridium difficile</i> in the gastrointestinal tract. <i>Anaerobe</i> , 2016 , 41, 44-50	2.8	68
31	Shifts in the Gut Metabolome and Transcriptome throughout Colonization and Infection in a Mouse Model. <i>MSphere</i> , 2018 , 3,	5	54
30	Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to <i>Clostridium difficile</i> infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2767-74	5.9	53

29	Targeting of <i>Clostridioides difficile</i> Using Phage-Delivered CRISPR-Cas3 Antimicrobials. <i>MBio</i> , 2020 , 11,	7.8	50
28	Microbial and metabolic interactions between the gastrointestinal tract and <i>Clostridium difficile</i> infection. <i>Gut Microbes</i> , 2014 , 5, 86-95	8.8	50
27	The Bile Salt Hydrolase Repertoire Reveals Niche-Specific Adaptation. <i>MSphere</i> , 2018 , 3,	5	43
26	Cefoperazone-treated Mouse Model of Clinically-relevant <i>Clostridium difficile</i> Strain R20291. <i>Journal of Visualized Experiments</i> , 2016 ,	1.6	26
25	<i>Clostridioides difficile</i> exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota. <i>Nature Communications</i> , 2021 , 12, 462	17.4	26
24	Improving the catalytic activity of hyperthermophilic <i>Pyrococcus horikoshii</i> prolidase for detoxification of organophosphorus nerve agents over a broad range of temperatures. <i>Archaea</i> , 2011 , 2011, 565127	2	23
23	bile salt hydrolase substrate specificity governs bacterial fitness and host colonization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	23
22	Intestinal bile acids directly modulate the structure and function of TcdB toxin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 6792-6800	11.5	18
21	Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during <i>Clostridioides difficile</i> Infection by Altering Gut Bile Acids. <i>Infection and Immunity</i> , 2020 , 88,	3.7	17
20	Effects of tigecycline and vancomycin administration on established <i>Clostridium difficile</i> infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1596-604	5.9	10
19	Dosing Regimen of Enrofloxacin Impacts Intestinal Pharmacokinetics and the Fecal Microbiota in Steers. <i>Frontiers in Microbiology</i> , 2018 , 9, 2190	5.7	10
18	A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against. <i>Frontiers in Microbiology</i> , 2018 , 9, 1206	5.7	9
17	Role of Microbiota-Derived Bile Acids in Enteric Infections. <i>Cell</i> , 2020 , 181, 1452-1454	56.2	8
16	<i>Clostridium difficile</i> -induced colitis in mice is independent of leukotrienes. <i>Anaerobe</i> , 2014 , 30, 90-8	2.8	7
15	Salicylanilide Analog Minimizes Relapse of Infection in Mice. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 6898-6908	8.3	5
14	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal <i>Escherichia coli</i> , and the microbiome of steers. <i>PLoS ONE</i> , 2019 , 14, e0223378	3.7	5
13	Mechanisms of Colonization Resistance Against <i>Clostridioides difficile</i> . <i>Journal of Infectious Diseases</i> , 2021 , 223, S194-S200	7	5
12	Contribution of Inhibitory Metabolites and Competition for Nutrients to Colonization Resistance against by Commensal. <i>Microorganisms</i> , 2021 , 9,	4.9	3

11	Beyond Structure: Defining the Function of the Gut Using Omic Approaches for Rational Design of Personalized Therapeutics. <i>MSystems</i> , 2018 , 3,	7.6	2
10	Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. <i>PLoS ONE</i> , 2021 , 16, e0246161	3.7	2
9	Complete Genome Sequence of <i>Lactobacillus johnsonii</i> NCK2677, Isolated from Mice. <i>Microbiology Resource Announcements</i> , 2020 , 9,	1.3	1
8	Prolonged oral antimicrobial administration prevents doxorubicin-induced loss of active intestinal stem cells.. <i>Gut Microbes</i> , 2022 , 14, 2018898	8.8	0
7	The Stickland Reaction Precursor -4-Hydroxy-L-Proline Differentially Impacts the Metabolism of <i>Clostridioides difficile</i> and Commensal .. <i>MSphere</i> , 2022 , e0092621	5	0
6	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal <i>Escherichia coli</i> , and the microbiome of steers 2019 , 14, e0223378		
5	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal <i>Escherichia coli</i> , and the microbiome of steers 2019 , 14, e0223378		
4	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal <i>Escherichia coli</i> , and the microbiome of steers 2019 , 14, e0223378		
3	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal <i>Escherichia coli</i> , and the microbiome of steers 2019 , 14, e0223378		
2	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal <i>Escherichia coli</i> , and the microbiome of steers 2019 , 14, e0223378		
1	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal <i>Escherichia coli</i> , and the microbiome of steers 2019 , 14, e0223378		